These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 15453958)

  • 1. [18F]3'-deoxy-3'-fluorothymidine-PET in NHL patients: whole-body biodistribution and imaging of lymphoma manifestations--a pilot study.
    Buchmann I; Neumaier B; Schreckenberger M; Reske S
    Cancer Biother Radiopharm; 2004 Aug; 19(4):436-42. PubMed ID: 15453958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early determination of prognosis by interim 3'-deoxy-3'-18F-fluorothymidine PET in patients with non-Hodgkin lymphoma.
    Lee H; Kim SK; Kim YI; Kim TS; Kang SH; Park WS; Yun T; Eom HS
    J Nucl Med; 2014 Feb; 55(2):216-22. PubMed ID: 24365650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early response assessment using 3'-deoxy-3'-[18F]fluorothymidine-positron emission tomography in high-grade non-Hodgkin's lymphoma.
    Herrmann K; Wieder HA; Buck AK; Schöffel M; Krause BJ; Fend F; Schuster T; Meyer zum Büschenfelde C; Wester HJ; Duyster J; Peschel C; Schwaiger M; Dechow T
    Clin Cancer Res; 2007 Jun; 13(12):3552-8. PubMed ID: 17575218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular imaging of proliferation in malignant lymphoma.
    Buck AK; Bommer M; Stilgenbauer S; Juweid M; Glatting G; Schirrmeister H; Mattfeldt T; Tepsic D; Bunjes D; Mottaghy FM; Krause BJ; Neumaier B; Döhner H; Möller P; Reske SN
    Cancer Res; 2006 Nov; 66(22):11055-61. PubMed ID: 17108145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [18F]5-fluoro-2-deoxyuridine-PET for imaging of malignant tumors and for measuring tissue proliferation.
    Buchmann I; Vogg AT; Glatting G; Schultheiss S; Möller P; Leithäuser F; Schulte M; Gfrörer W; Kotzerke J; Reske SN
    Cancer Biother Radiopharm; 2003 Jun; 18(3):327-37. PubMed ID: 12954120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigating the existence of quantum metabolic values in non-Hodgkin's lymphoma by 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography.
    Wong CY; Thie J; Parling-Lynch KJ; Zakalik D; Wong RH; Gaskill M; Margolis JH; Hill J; Sukari A; Chundru S; Fink-Bennett D; Nagle C
    Mol Imaging Biol; 2007; 9(1):43-9. PubMed ID: 17176979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of 3'-deoxy-3'-[18F]fluorothymidine PET/CT for evaluating response to cytotoxic chemotherapy in dogs with non-Hodgkin's lymphoma.
    Lawrence J; Vanderhoek M; Barbee D; Jeraj R; Tumas DB; Vail DM
    Vet Radiol Ultrasound; 2009; 50(6):660-8. PubMed ID: 19999354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma.
    Schöder H; Noy A; Gönen M; Weng L; Green D; Erdi YE; Larson SM; Yeung HW
    J Clin Oncol; 2005 Jul; 23(21):4643-51. PubMed ID: 15837966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imaging of proliferation in hepatocellular carcinoma with the in vivo marker 18F-fluorothymidine.
    Eckel F; Herrmann K; Schmidt S; Hillerer C; Wieder HA; Krause BJ; Schuster T; Langer R; Wester HJ; Schmid RM; Schwaiger M; Buck AK
    J Nucl Med; 2009 Sep; 50(9):1441-7. PubMed ID: 19690030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG.
    Chen W; Cloughesy T; Kamdar N; Satyamurthy N; Bergsneider M; Liau L; Mischel P; Czernin J; Phelps ME; Silverman DH
    J Nucl Med; 2005 Jun; 46(6):945-52. PubMed ID: 15937304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Whole-body diffusion-weighted MRI and (18)F-FDG PET/CT can discriminate between different lymphoma subtypes.
    Mosavi F; Wassberg C; Selling J; Molin D; Ahlström H
    Clin Radiol; 2015 Nov; 70(11):1229-36. PubMed ID: 26208992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of 18F-FLT PET and 18F-FDG PET in esophageal cancer.
    van Westreenen HL; Cobben DC; Jager PL; van Dullemen HM; Wesseling J; Elsinga PH; Plukker JT
    J Nucl Med; 2005 Mar; 46(3):400-4. PubMed ID: 15750150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Standardized uptake value based evaluation of lymphoma by FDG and FLT PET/CT.
    Wang R; Zhu H; Chen Y; Li C; Li F; Shen Z; Tian J; Yu L; Xu B
    Hematol Oncol; 2014 Sep; 32(3):126-32. PubMed ID: 23996464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does partial volume corrected maximum SUV based on count recovery coefficient in 3D-PET/CT correlate with clinical aggressiveness of non-Hodgkin's lymphoma?
    Tsujikawa T; Otsuka H; Morita N; Saegusa H; Kobayashi M; Okazawa H; Nishitani H
    Ann Nucl Med; 2008 Jan; 22(1):23-30. PubMed ID: 18250984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Whole-body biodistribution of 3'-deoxy-3'-[(18) f]fluorothymidine ((18) FLT) in healthy adult cats.
    Rowe JA; Morandi F; Wall JS; Akula M; Kennel SJ; Osborne D; Martin EB; Galyon GD; Long MJ; Stuckey AC; LeBlanc AK
    Vet Radiol Ultrasound; 2013; 54(3):299-306. PubMed ID: 23464567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is 18F-3'-fluoro-3'-deoxy-L-thymidine useful for the staging and restaging of non-small cell lung cancer?
    Cobben DC; Elsinga PH; Hoekstra HJ; Suurmeijer AJ; Vaalburg W; Maas B; Jager PL; Groen HM
    J Nucl Med; 2004 Oct; 45(10):1677-82. PubMed ID: 15471832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First demonstration of leukemia imaging with the proliferation marker 18F-fluorodeoxythymidine.
    Buck AK; Bommer M; Juweid ME; Glatting G; Stilgenbauer S; Mottaghy FM; Schulz M; Kull T; Bunjes D; Möller P; Döhner H; Reske SN
    J Nucl Med; 2008 Nov; 49(11):1756-62. PubMed ID: 18927328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 3'-[18F]fluoro-3'-deoxythymidine ([18F]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-Cell lymphoma model and in the human disease.
    Wagner M; Seitz U; Buck A; Neumaier B; Schultheiss S; Bangerter M; Bommer M; Leithäuser F; Wawra E; Munzert G; Reske SN
    Cancer Res; 2003 May; 63(10):2681-7. PubMed ID: 12750297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigation of FDG-PET/CT imaging to guide biopsies in the detection of histological transformation of indolent lymphoma.
    Bodet-Milin C; Kraeber-Bodéré F; Moreau P; Campion L; Dupas B; Le Gouill S
    Haematologica; 2008 Mar; 93(3):471-2. PubMed ID: 18310543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early reduction in tumour [18F]fluorothymidine (FLT) uptake in patients with non-small cell lung cancer (NSCLC) treated with radiotherapy alone.
    Trigonis I; Koh PK; Taylor B; Tamal M; Ryder D; Earl M; Anton-Rodriguez J; Haslett K; Young H; Faivre-Finn C; Blackhall F; Jackson A; Asselin MC
    Eur J Nucl Med Mol Imaging; 2014 Apr; 41(4):682-93. PubMed ID: 24504503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.